AtriCure to Announce Third Quarter 2019 Financial Results
October 08 2019 - 8:00AM
Business Wire
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments
for atrial fibrillation (Afib) and left atrial appendage (LAA)
management, today announced that it will release its third quarter
2019 financial results on Wednesday, October 30, 2019.
AtriCure will host a conference call at 4:30 p.m. Eastern Time
on Wednesday, October 30, 2019 to discuss its third quarter 2019
financial results. The call may be accessed through an operator by
calling (844) 884-9951 for domestic callers and (661) 378-9661 for
international callers using conference ID number 7039247. A live
audio webcast of the presentation may be accessed by visiting the
Investors page of AtriCure’s corporate website at ir.atricure.com.
A replay of the presentation will be available for 90 days
following the presentation.
About AtriCure
AtriCure, Inc. provides innovative technologies for the
treatment of Afib and related conditions. Afib affects more than 33
million people worldwide. Electrophysiologists and cardiothoracic
surgeons around the globe use AtriCure technologies for the
treatment of Afib and reduction of Afib related complications.
AtriCure’s Isolator® Synergy™ Ablation System is the first and only
medical device to receive FDA approval for the treatment of
persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage
Exclusion System products are the most widely sold left atrial
appendage management devices worldwide. For more information, visit
AtriCure.com or follow us on Twitter @AtriCure.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191008005092/en/
Andy Wade AtriCure, Inc. Senior Vice President and Chief
Financial Officer (513) 755-4564 awade@atricure.com
Lynn Pieper Lewis Gilmartin Group Investor Relations (415)
937-5402 lynn@gilmartinir.com
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Mar 2024 to Apr 2024
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Apr 2023 to Apr 2024